Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

39 citing papers in PubMed.

1. Effects of Combining Immune-Priming Sub-Lethal Low-Dose Radiation with 4-1BB Activation and Gal-3 Blockade in In Vitro and Preclinical Group-3 Medulloblastoma Models.Cancers · 2026
   Article
2. A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies.Cancer cell · 2026
   Article
3. Medulloblastoma stem cell programs: Molecular roadmaps of disease progression.Developmental cell · 2026
   Review
4. Neuron-specific expression of murine thyroid hormone transporters Mct8 and Oatp1c1 is dispensable for hippocampus-dependent neuronal functions.Frontiers in endocrinology · 2026
   Article
5. Investigation of a global mouse methylome atlas reveals subtype-specific copy number alterations in pediatric cancer models.Nature genetics · 2026
   Article
6. Genetic markers and canonical pathways associated with medulloblastoma: a systematic review and meta-analysis.Translational pediatrics · 2025
   Article
7. Current State-of-the-Art Animal Models of Pediatric Brain Tumors.Brain sciences · 2025
   Review
8. NeKo: A tool for automatic network construction from prior knowledge.PLoS computational biology · 2025
   Article
9. Optimized toolkit for the manipulation of immortalized axolotl fibroblasts.Methods (San Diego, Calif.) · 2025
   Article
10. Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS.Cell reports · 2025
    Article
11. MYC-dependent upregulation of the de novo serine and glycine synthesis pathway is a targetable metabolic vulnerability in group 3 medulloblastoma.Neuro-oncology · 2025
    Article
12. Arrested development: the dysfunctional life history of medulloblastoma.Genes & development · 2025
    Review
13. Epigenetic modifications and their roles in pediatric brain tumor formation: emerging insights from chromatin dysregulation.Frontiers in oncology · 2025
    Review
14. Medulloblastoma: biology and immunotherapy.Frontiers in immunology · 2025
    Review
15. Group 3 medulloblastoma transcriptional networks collapse under domain specific EP300/CBP inhibition.Nature communications · 2024
    Article
16. Heterogeneity and tumoral origin of medulloblastoma in the single-cell era.Oncogene · 2024
    Review
17. Translation of non-canonical open reading frames as a cancer cell survival mechanism in childhood medulloblastoma.Molecular cell · 2024
    Article
18. MYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice.Acta neuropathologica communications · 2023
    Article
19. ARF suppression by MYC but not MYCN confers increased malignancy of aggressive pediatric brain tumors.Nature communications · 2023
    Article
20. Unified rhombic lip origins of group 3 and group 4 medulloblastoma.Nature · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

20 authors.

Funding

Abstract

Indexed as